Short answer
Vertex Pharmaceuticals (VRTX) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.4B (up 11.8% year over year) with net income of $654M.
Q3 2026 key financials · XBRL
- Revenue
- $3.4B
- +11.8% YoY · +3.2% QoQ
- Net income
- $654M
- −39.6% YoY · −40.6% QoQ
- Operating margin
- 20.7%
- EPS (diluted)
- $2.57
- −38.8% YoY · −40.4% QoQ
Source: XBRL data from the Vertex Pharmaceuticals (VRTX) Q3 2026 10-Q on SEC EDGAR. USD.
Vertex Pharmaceuticals Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $3,440.8M, up 12% YoY from $3,076.4M
- Cost-of-sales margin 15.3% vs 13.5% YoY; total costs and expenses $2,727.9M, up 44%
- Best product: ALYFTREK revenue $705.8M, up 186%; weakest: TRIKAFTA/KAFTRIO $2,436.9M, down 8%
- Cash, equivalents and securities $9,821.2M, down 20% from $12,320.4M; nine-month operating cash flow $3,196.6M
- Crinetics acquisition consumed $9.1B net cash; $4.5B term loan increased future interest expense and debt repayments through 2029
Risk Factors
- Newly added risk: Crinetics integration, including potential failure to retain key employees or realize synergies
- Most materially updated risk: PALSONIFY and atumelnant may miss expected commercial performance or development timelines
- Regulatory risk: povetacicept accelerated-approval review carries a November 30, 2026 PDUFA target action date
- Operational risk: Integration activities could disrupt ongoing business and divert management attention
- Financial risk: Crinetics acquisition benefits depend on future revenues from PALSONIFY and atumelnant
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vertex Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.